OTTAWA, Ontario–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, is pleased to announce that a seminal paper, written by scientists from South China Agricultural University, which reports “The effects of maternal supplementation with fully oxidised β-carotene on the reproductive performance and immune response of sows, as well as the growth performance of nursing piglets” has been accepted for publication by the British Journal of Nutrition. Established in 1947 and published by Cambridge University Press, the prestigious British Journal of Nutrition is an international peer-reviewed scientific journal publishing original papers and review articles across the full spectrum of nutritional science, covering research on animal and human nutrition.

“The effects of maternal supplementation with fully oxidised β-carotene on the reproductive performance and immune response of sows, as well as the growth performance of nursing piglets”

Tweet this

Jamie Nickerson, Avivagen’s Executive VP Business Development and Product Innovation, commented “The study showed a definite improvement in a number of colostrum and milk quality parameters, including the concentration of antibodies and other important immunological factors. Transfer of antibodies from the sow to piglets via the colostrum and milk provides critical disease-protection to suckling piglets whose immune systems are still immature. Given the improved colostrum and milk quality it was not surprising that the results also suggested that litters from OxC-beta-fed sows remained healthier and weaned heavier compared to controls. Improvement in the overall health of the sows fed OxC-beta represents the likely explanation for the observed benefits to colostrum and milk quality. There were apparent improvements in other measures of sow health as well, including reduced weight loss during lactation, a higher percentage of sows returning to estrus earlier, and fewer undersized piglets at birth. The industry recognizes that the results are indicative of real benefits and we have had a number of customers testing OxC-beta in their own sow herds.”

“The publication of this paper will help the scientific community and the health sciences industry in general to understand the power of our discovery. Furthermore, publication of studies in peer-reviewed scientific literature provides important validation of the results that feed industry clients look for,” added Kym Anthony, Avivagen’s Chief Executive Officer. “We continue to discover new and beneficial applications of OxC-beta™ with the anticipation of additional peer-reviewed publications.”

The free access publication is available at:

About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Taiwan, New Zealand, Thailand, Mexico, Brazil, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that in some aspects the product performs as well as, and sometimes better than in-feed antibiotics.

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements set out in this news release relating to the continued distribution and acceptance of Avivagen’s technology, anticipated adoption of and growth in demand for Avivagen’s products, the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded, the size of market opportunities and the potential benefits of the relationship with Look Chemicals are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the regulatory approval may not result in new orders for Avivagen’s products in Brazil, Avivagen’s products may not gain market acceptance or regulatory approval in other new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds, new market access may not occur in the timeline or manner expected by Avivagen, the market opportunities may not be as large as Avivagen anticipates and the anticipated benefits of the Look Chemicals relationship may not be achieved due to many factors, many of which are outside of Avivagen’s control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright © 2020 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.


Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733

Kym Anthony
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164


Please enter your comment!
Please enter your name here